William Blair Has Pessimistic Outlook of LRMR Q1 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at William Blair dropped their Q1 2025 earnings estimates for shares of Larimar Therapeutics in a report released on Monday, December 16th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.35) per share for the quarter, down from their previous forecast of ($0.32). William Blair has a "Outperform" rating on the stock. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.16) per share. William Blair also issued estimates for Larimar Therapeutics' Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.64) EPS, FY2026 earnings at ($1.81) EPS, FY2027 earnings at ($1.83) EPS and FY2028 earnings at ($0.19) EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.13. During the same quarter last year, the company earned ($0.21) earnings per share.

A number of other research analysts have also recently commented on the company. Wedbush initiated coverage on Larimar Therapeutics in a research report on Thursday, October 3rd. They issued an "outperform" rating and a $22.00 price target on the stock. Baird R W raised shares of Larimar Therapeutics to a "strong-buy" rating in a report on Wednesday, September 4th. Oppenheimer initiated coverage on shares of Larimar Therapeutics in a report on Wednesday, October 16th. They set an "outperform" rating and a $26.00 price target for the company. Robert W. Baird assumed coverage on shares of Larimar Therapeutics in a research report on Wednesday, September 4th. They set an "outperform" rating and a $16.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Larimar Therapeutics in a research report on Monday. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $20.43.

Larimar Therapeutics Trading Down 4.3 %

NASDAQ LRMR traded down $0.18 during midday trading on Thursday, hitting $3.98. The company had a trading volume of 1,552,424 shares, compared to its average volume of 626,714. The firm has a 50-day moving average price of $6.97 and a 200-day moving average price of $7.65. The company has a market capitalization of $253.95 million, a PE ratio of -3.46 and a beta of 0.86. Larimar Therapeutics has a twelve month low of $3.01 and a twelve month high of $13.68.

Institutional Trading of Larimar Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP lifted its stake in shares of Larimar Therapeutics by 966.7% in the 2nd quarter. Quarry LP now owns 8,000 shares of the company's stock valued at $58,000 after acquiring an additional 7,250 shares during the last quarter. Quest Partners LLC increased its holdings in Larimar Therapeutics by 171.1% in the 3rd quarter. Quest Partners LLC now owns 9,183 shares of the company's stock worth $60,000 after purchasing an additional 5,796 shares in the last quarter. Virtu Financial LLC acquired a new position in Larimar Therapeutics in the 3rd quarter worth about $71,000. Intech Investment Management LLC bought a new position in Larimar Therapeutics in the third quarter valued at about $85,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Larimar Therapeutics during the third quarter valued at about $94,000. Institutional investors and hedge funds own 91.92% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.